公开(公告)号：US20230407262A1

公开(公告)日：2023-12-21

申请号：US18055409

申请日：2022-11-14

Applicant: Gwo Xi Stem Cell Applied Technology Co., Ltd.

Inventor： Wei Wu Li ,  Tzyy-Wen Chiou ,  Horng-Jyh Harn ,  Shinn-Zong Lin ,  Ming-Hsi Chuang ,  Po-Cheng Lin ,  Chia-Hsin Lee ,  Mao-Hsuan Huang

IPC: C12N5/0775 ,  C12N5/079 ,  C07K14/435 ,  A61K38/17 ,  A61P25/00

CPC classification number: C12N5/0663 ,  C12N5/0618 ,  C07K14/435 ,  A61K38/17 ,  A61P25/00

Abstract: The present invention provides a medicine for treating a neurodegenerative disease, which employs LEFTY2 (Left-Right Determination Factor 2) generated by co-culturing mesenchymal stem cells of mammals with nerve cells having mutations in the APP (Amyloid precursor protein) gene, or a specific protein. The LEFTY2 has an effect of inhibiting Beta amyloid and a hyperphosphorylated neuronal microtubule-associated protein (Tau protein), without affecting the development of nerve cells and having the ability to promote the growth of the nerve cells; and the two types of proteins have a crucial impact on the neurodegenerative diseases.